
Sanyou Biopharmaceuticals and Baiyunshan Xihe Health Pharmaceutical have signed a strategic cooperation agreement to co-develop novel radiopharmaceuticals and radiodiagnostic products, pairing artificial intelligence (AI)-based molecular discovery with nuclear medicine manufacturing and clinical translation capabilities.
The Chinese companies said the alliance is intended to build an end-to-end innovation chain, running from target molecule discovery through to clinical development of radiopharmaceutical candidates for precision oncology diagnosis and therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze